PITTSBURGH, Pa. — GNC has announced the release of a landmark peer-reviewed paper providing new clinical insights into how dietary supplements can support GLP-1 medications like Ozempic and Wegovy. The article, titled “Dietary Supplement Considerations During Glucagon-like Peptide-1 Receptor Agonist Treatment: A Narrative Review,” is published in Obesity Pillars and highlights GNC’s expanding leadership in evidence-based nutrition.
The review, written by GNC’s research team, highlights a significant gap in the expanding field of GLP-1–based weight management: the absence of official guidance on how supplements can support muscle health, nutrition, and overall wellness for those using GLP-1 therapies.
“Patients are increasingly turning to weight loss medications, yet little peer-reviewed guidance exists on how to integrate dietary supplements alongside GLP-1 treatment with diet and exercise,” said Dr. Brittany Johnson, lead author of the paper. “This paper helps close that gap by providing evidence-based data that can be applied from prior weight loss science, while paving the way for future research combining GLP-1 and supplement interventions.”
The publication summarizes existing evidence and provides actionable recommendations for supplement integration during GLP-1 treatment, including:
- Multivitamins and Vitamin D to address common nutrient deficiencies.
- Omega-3s to support heart health and muscle quality.
- Protein, Creatine, and HMB to preserve lean mass during weight loss.
- Antioxidants such as Curcumin, CoQ10, and Polyphenols to reduce oxidative stress.
- Fiber and Probiotics to improve digestion and mitigate gastrointestinal side effects.
- Thermogenics like caffeine or green tea extract to increase energy expenditure.
The review is part of GNC’s broader research initiative, which also produced the first published study examining nutrient intake among GLP-1 users. A new clinical trial is currently underway to evaluate the impact of GLP-1 treatments on nutritional habits, body composition, and health outcomes.
“Our research directly informs how we design products and build our GLP-1-focused portfolio,” said Rachel Kreider, Vice President of Product Innovation and Science at GNC. “By understanding the unique needs of this growing population, we can deliver tailored nutrition solutions that are rooted in science and aligned with consumer health goals.”
The paper serves as the scientific foundation for GNC’s GLP-1 support initiative, which integrates research, product innovation, and education for consumers and healthcare professionals. Through continued investment in clinical studies and academic partnerships, GNC aims to strengthen its role as a trusted leader in personalized, science-based nutrition for individuals using GLP-1 medications.
For more information, visit www.gnc.com.
